Forgot your password?

Enter the email address for your account and we'll send you a verification to reset your password.

Your email address
Your new password
It’s a time when cancer is spreading by leaps and bound across the globe, and this Israeli biotech company has claimed that they will have the cure for this deadly disease by 2020.
It’s a well-known fact that types of treatments are available in the market, but nothing really takes up the challenge to cure this deadly disease 100%. But Accelerated Evolution Biotechnologies Ltd (AEBi), founded in 2000 from the ITEK Weizmann technology incubator has made a strong claim that they can cure this disease completely.

It was in an interview with a leading daily, Aridor, chairman of the board of AEBi, has acclaimed that their cure for cancer will be put to effect from the very first day and will last for a few weeks. Also, their medicines will have “no or minimal side-effects”. He further added that the cure for cancer will be available at a much reasonable rate than other expensive treatments available in the market.

The treatment is named by the biotech company MuTaTo (multi-target toxin) is based on SoAP technology, which belongs to the phage display group of technologies.
The CEO of the biotech company Dr. Ilan Morad asserted that they’ve started identifying why other cancer-related drugs and treatment are not working and then they found an effective way to combat it.

“Instead of attacking receptors one at a time, we attack receptors three at a time. Not even cancer can mutate three receptors at one time," said Morad, to the daily newspaper.
It happened after a successful mice trail that Morad said, the company is now prepping up to try medicines on humans through this year. Following this, they will introduce the medicine in the market by next year.
This particular claim came in as bliss when around 18. 1 million new cases of cancer are being diagnosed every year around the globe.
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0

Add you Response

  • Please add your comment.